MA

Mainz BioMed N.V.

Develops at-home diagnostic tests for the early detection of life-threatening cancers.

F

Overview

Corporate Details

ISIN(s):
NL0015000LC2 (+3 more)
LEI:
894500XWJE7LIJNYQ547
Country:
Germany
Address:
Robert-Koch-Strasse 50, 55129 Mainz
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Mainz BioMed N.V. is a molecular genetics company that develops and commercializes market-ready in-vitro diagnostic (IVD) solutions for the early detection of life-threatening conditions. The company's flagship product, ColoAlert®, is a non-invasive, at-home screening test for colorectal cancer (CRC) marketed in Europe. Mainz BioMed is also advancing its product pipeline with proprietary genetic testing methods for other deadly conditions, including pancreatic cancer, to provide accessible and reliable early detection solutions.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-15 15:01
Regulatory News Service
Mainz Biomed to Attend 2025 Maxim Growth Summit
English 10.2 KB
2025-10-08 15:00
Regulatory News Service
Mainz Biomed Reports Topline Results from Feasibility Study of Biomarker Panel …
English 12.2 KB
2025-09-30 14:01
Regulatory News Service
Mainz Biomed to Present the Future of Colorectal Cancer Screening at WEO CRC Sc…
English 12.1 KB
2025-09-23 14:01
Regulatory News Service
Mainz Biomed Announces Commercial Launch of ColoAlert in Switzerland
English 11.5 KB
2025-09-02 14:01
Regulatory News Service
Mainz Biomed Announces Registration of ColoAlert in the United Kingdom
English 11.2 KB
2025-08-13 14:01
Regulatory News Service
Mainz Biomed Receives Swiss Regulatory Approval to Market ColoAlert
English 11.6 KB
2025-07-23 14:01
Business and Financial Review
Mainz Biomed and CARE Conclude Cooperation Agreement for Joint Care Concept for…
English 11.2 KB
2025-07-15 14:01
Earnings Release
Mainz Biomed Half Year 2025 Update: Accelerating FDA Pathway for NextGen Colore…
English 15.5 KB
2025-06-25 14:01
Regulatory News Service
Mainz Biomed Secures Public Funding to Advance Innovative Pancreatic Cancer Scr…
English 11.1 KB

Automate Your Workflow. Get a real-time feed of all Mainz BioMed N.V. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Mainz BioMed N.V.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Mainz BioMed N.V. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Newbury Pharmaceuticals AB Logo
Develops specialty prescription drugs for Scandinavia in oncology, rare diseases & neurology.
Sweden NEWBRY
New Nordic Healthbrands AB Logo
Develops and markets herbal supplements & beauty products for natural wellness consumers globally.
Sweden NNH
Newron Pharmaceuticals S.p.A. Logo
Biopharma developing novel therapies for nervous system diseases like Parkinson's and schizophrenia.
Italy NWRN
NextCell Pharma AB Logo
Develops off-the-shelf cell therapies for autoimmune diseases like type 1 diabetes.
Sweden NXTCL
NGeneBio Co., Ltd. Logo
Provides NGS-based diagnostics, software, and liquid biopsy for precision oncology and healthcare.
South Korea 354200
NIBEC CO., LTD. Logo
Biotech CDMO creating regenerative products with peptide and biomaterial technologies.
South Korea 138610
NIPPON CHEMIPHAR CO., LTD. Logo
Develops generic drugs, allergy treatments, and novel pharmaceuticals for a global market.
Japan 4539
Nippon Shinyaku Co.,Ltd. Logo
Develops pharmaceuticals and functional foods to improve healthcare and wellbeing.
Japan 4516
NKMAX Co., Ltd. Logo
Biotech firm for NK cell therapies, global research reagents, diagnostics, and supplements.
South Korea 182400
Novacyt Logo
Designs and supplies molecular diagnostic tests and PCR kits for human, veterinary, and food safety.
France ALNOV

Talk to a Data Expert

Have a question? We'll get back to you promptly.